Fig. 5

AZD5069 prevents the deterioration of hepatic parenchyma, reduces fibrosis, steatosis, lobulation, and hepatocyte ballooning under high fat diet conditions. The graph shows the median NAFLD Activity Score (NAS) comprised of pathologist-determined scores indicative of steatohepatitis (NASH), inconclusive of steatohepatitis (Borderline) and absence of steatohepatits (Health). H&E liver sections procured from n = 12 mice on 16 weeks of the CN, HF, and HF + AZD diet arms were evaluated for their clinical NAS Score, which consists of steatosis, lobulation, inflammation, and hepatocyte ballooning. A trend in fibrosis improvement was observed in liver sections from mice on HF + AZD at 16 weeks, however it failed to reach statistical significance when compared to assessments of liver sections from mice on HF diet. The graph represents the median of scores assigned by two independent pathologists (n = 12 mice per diet arm). C–E Positivity for Col1a1, α-SMA, and Galectin-3 in immunofluorescence in serial sections of livers from mice among the three diet arms at 16 weeks (n = 7 mice per diet arm). The bars in each graph show the median of each of the measurements among mice in each of the diet arms and the error bars show the SD. Statistical analysis was performed by Fisher’s Exact test followed by a Cochran-Armitage post-test for trend or the Kruskal–Wallis test followed by Bonferroni post-test. Significant differences depicted with (*) were p < 0.05, (**) were p < 0.01, and (****) were p < 0.0001